X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (119) 119
index medicus (119) 119
somatostatinoma (56) 56
pancreatic neoplasms - diagnosis (51) 51
female (47) 47
somatostatinoma - diagnosis (47) 47
male (43) 43
middle aged (43) 43
pancreatic neoplasms - therapy (42) 42
somatostatinoma - therapy (33) 33
surgery (32) 32
glucagonoma - diagnosis (28) 28
adult (27) 27
aged (26) 26
pancreatic neoplasms - pathology (26) 26
gastroenterology & hepatology (25) 25
tumors (25) 25
vipoma - diagnosis (25) 25
pancreas (24) 24
somatostatinoma - pathology (24) 24
pancreatic neoplasms - surgery (23) 23
somatostatinoma - surgery (23) 23
glucagonoma - therapy (22) 22
oncology (22) 22
abridged index medicus (21) 21
insulinoma (21) 21
insulinoma - diagnosis (21) 21
gastrinoma (20) 20
neuroendocrine tumors (19) 19
vipoma (19) 19
vipoma - therapy (19) 19
glucagonoma (18) 18
insulinoma - therapy (17) 17
diagnosis, differential (16) 16
endocrinology & metabolism (15) 15
somatostatinoma - complications (15) 15
zollinger-ellison syndrome (15) 15
zollinger-ellison-syndrome (14) 14
adenoma, islet cell - diagnosis (13) 13
diagnosis (13) 13
endocrine tumors (13) 13
gastrinoma - diagnosis (13) 13
medicine & public health (13) 13
pancreatic neoplasms - complications (13) 13
prognosis (13) 13
somatostatinoma - diagnostic imaging (13) 13
islet-cell tumors (12) 12
neuroendocrine tumor (12) 12
neurofibromatosis (12) 12
pancreatic neoplasms - metabolism (12) 12
somatostatin (12) 12
carcinoid-tumors (11) 11
gastrinoma - therapy (11) 11
pheochromocytoma (11) 11
tomography, x-ray computed (11) 11
duodenal somatostatinoma (10) 10
liver neoplasms - secondary (10) 10
management (10) 10
neuroendocrine tumors - diagnosis (10) 10
pancreatic somatostatinoma (10) 10
pathology (10) 10
carcinoid (9) 9
clinical-features (9) 9
disease (9) 9
neuroendocrine tumors - therapy (9) 9
pancreatic neoplasms - diagnostic imaging (9) 9
pancreatic neoplasms - drug therapy (9) 9
pancreatic neoplasms - secretion (9) 9
somatostatinoma - metabolism (9) 9
somatostatinoma - secondary (9) 9
adenoma, islet cell - therapy (8) 8
immunohistochemistry (8) 8
multiple endocrine neoplasia (8) 8
neurofibromatosis 1 - complications (8) 8
octreotide - therapeutic use (8) 8
pancreatic endocrine tumors (8) 8
somatostatinoma - drug therapy (8) 8
zollinger-ellison syndrome - diagnosis (8) 8
zollinger-ellison syndrome - therapy (8) 8
adenoma, islet cell - pathology (7) 7
glucagonoma syndrome (7) 7
insulinoma - surgery (7) 7
localization (7) 7
medicine, general & internal (7) 7
metastasis (7) 7
neoplasm staging (7) 7
retrospective studies (7) 7
somatostatin - metabolism (7) 7
somatostatinoma - epidemiology (7) 7
treatment outcome (7) 7
apudoma - diagnosis (6) 6
apudoma - therapy (6) 6
cancer (6) 6
carcinoma (6) 6
combined modality therapy (6) 6
features (6) 6
gastrinoma - surgery (6) 6
gastroenterology and hepatology (6) 6
glucagonoma - pathology (6) 6
glucagonoma - surgery (6) 6
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (118) 118
French (4) 4
German (4) 4
Hungarian (3) 3
Japanese (3) 3
Spanish (3) 3
Korean (2) 2
Polish (2) 2
Danish (1) 1
Dutch (1) 1
Finnish (1) 1
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Endocrine-Related Cancer, ISSN 1351-0088, 12/2016, Volume 23, Issue 12, pp. 899 - 908
Journal Article
European Journal of Cancer, ISSN 0959-8049, 11/2017, Volume 86, pp. 1 - 4
Paragangliomas (PGLs) belong to the most hereditary endocrine tumours. The existence of mutated HIF2A in these tumours, the role of oncometabolites on HIFs... 
Hypoxia-inducible factor | Paraganglioma | von Hippel-Lindau | Renal cell carcinoma | Krebs cycle | ANTAGONIST | PHEOCHROMOCYTOMA | ONCOLOGY | HYPOXIA | Sulfones - therapeutic use | Kidney Neoplasms - genetics | Humans | Carcinoma, Renal Cell - genetics | Tumor Microenvironment | Antineoplastic Agents - therapeutic use | Kidney Neoplasms - metabolism | Molecular Targeted Therapy | Indans - therapeutic use | Tumor Hypoxia | Basic Helix-Loop-Helix Transcription Factors - metabolism | Drug Design | Carcinoma, Renal Cell - drug therapy | Paraganglioma - pathology | Basic Helix-Loop-Helix Transcription Factors - genetics | Signal Transduction | Carcinoma, Renal Cell - pathology | Paraganglioma - genetics | Paraganglioma - drug therapy | Basic Helix-Loop-Helix Transcription Factors - antagonists & inhibitors | Carcinoma, Renal Cell - metabolism | Paraganglioma - metabolism | Kidney Neoplasms - pathology | Mutation | Kidney Neoplasms - drug therapy | Endothelial growth factors | Tumors | Hypoxia-inducible factors | Medical research | Endocrine system | Brain tumors | Abnormalities | Disorders | Clinical trials | Retina | Antagonists | Signal transduction | Signaling | Metabolites | Pituitary | Kidney cancer | Hypoxia | Tumorigenesis | Clear cell-type renal cell carcinoma | Index Medicus | polycythemia | somatostatinoma | retinal abnormalities | pituitary tumor | hypoxia-inducible factor | hemangioblastoma | paraganglioma | leiomyosarcoma | renal cell carcinoma | gastrointestinal stromal tumor | metabolomics | leiomyoma | Warburg effect
Journal Article
BBA - Molecular Cell Research, ISSN 0167-4889, 03/2013, Volume 1833, Issue 3, pp. 573 - 582
Foregut neuroendocrine tumors [NETs] usually pursuit a benign course, but some show aggressive behavior. The treatment of patients with advanced NETs is... 
Pancreatic endocrine tumors | Cell growth | Gastrointestinal hormones | Transactivation | Neuroendocrine tumors | CANCER-CELLS | LUNG | SIGNALING PATHWAYS | ACTIVATION | TYROSINE PHOSPHORYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | KINASE | PROTEIN-COUPLED RECEPTORS | GASTRIN-RELEASING-PEPTIDE | DNA-SYNTHESIS | CELL BIOLOGY | EXPRESSION | Pancreatic Neoplasms - metabolism | Reactive Oxygen Species - metabolism | Adenoma, Islet Cell - pathology | Humans | Transcriptional Activation | Gastrointestinal Hormones - pharmacology | Pancreatic Neoplasms - drug therapy | Somatostatinoma - metabolism | Receptor, Epidermal Growth Factor - metabolism | Somatostatinoma - drug therapy | Somatostatinoma - pathology | Adenoma, Islet Cell - drug therapy | Phosphorylation - drug effects | Tumor Cells, Cultured | Transforming Growth Factor alpha - pharmacology | Neuroendocrine Tumors - pathology | Neuroendocrine Tumors - metabolism | Pancreatic Neoplasms - pathology | Rats | Blotting, Western | Adenoma, Islet Cell - metabolism | Tyrosine - metabolism | Animals | Signal Transduction - drug effects | Neuroendocrine Tumors - drug therapy | Cell Proliferation - drug effects | Epidermal Growth Factor - pharmacology | Bombesin | Epidermal growth factor | Growth | Neurotensin | G proteins | Transforming growth factors | Vasoactive intestinal peptides | Phosphotransferases | Cancer
Journal Article
Hepato-Gastroenterology, ISSN 0172-6390, 09/2012, Volume 59, Issue 118, pp. 1874 - 1878
Journal Article
Tumori, ISSN 0300-8916, 09/2010, Volume 96, Issue 5, pp. 858 - 873
MAMMALIAN TARGET | RAPAMYCIN | ONCOLOGY | GROWTH | PANCREATIC BETA-CELLS | RECEPTOR | TUMOR-CELLS | NEUROFIBROMATOSIS | SOMATOSTATINOMA | CANCER | MTOR | Neuroendocrine Tumors - blood | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Recombinant Proteins | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Antibodies, Monoclonal, Humanized | Molecular Targeted Therapy - trends | Multicenter Studies as Topic | Insulinoma - blood | Organometallic Compounds - therapeutic use | Pyrroles - therapeutic use | Everolimus | Radiotherapy Planning, Computer-Assisted | Molecular Targeted Therapy - methods | Endostatins - therapeutic use | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Somatostatin - analogs & derivatives | Octreotide - analogs & derivatives | Neuroendocrine Tumors - metabolism | Insulinoma - drug therapy | Dopamine Antagonists - therapeutic use | Piperazines - therapeutic use | Octreotide - therapeutic use | Imatinib Mesylate | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Neuroendocrine Tumors - radiotherapy | Signal Transduction - drug effects | ACTH Syndrome, Ectopic - drug therapy | Pyrimidines - therapeutic use | Neuroendocrine Tumors - drug therapy | Peptides, Cyclic - therapeutic use | Indoles - therapeutic use | Benzamides | Somatostatin - therapeutic use | Radiopharmaceuticals - therapeutic use | Clinical Trials, Phase II as Topic
Journal Article
World Journal of Surgery, ISSN 0364-2313, 07/1992, Volume 16, Issue 4, pp. 632 - 639
Journal Article
Gut, ISSN 0017-5749, 06/1998, Volume 42, Issue 6, pp. 792 - 794
Journal Article
Journal Article
Best Practice & Research Clinical Gastroenterology, ISSN 1521-6918, 2005, Volume 19, Issue 5, pp. 753 - 781
Endocrine pancreatic tumours (EPTs) are uncommon tumours occurring in approximately 1 in 100 000 of the population, representing 1–2% of all pancreatic... 
molecular genetics | localization | histopathology | medical treatment | biochemistry | endocrine pancreatic tumours | Biochemistry | Histopathology | Molecular genetics | Localization | Medical treatment | Endocrine pancreatic tumours | Immunohistochemistry | Glucagonoma - drug therapy | Pancreatic Neoplasms - epidemiology | Prognosis | Molecular Biology | Humans | Carcinoma, Neuroendocrine - epidemiology | Male | Incidence | Insulinoma - epidemiology | Pancreatic Neoplasms - drug therapy | Glucagonoma - epidemiology | Somatostatinoma - drug therapy | Somatostatinoma - pathology | Zollinger-Ellison Syndrome - epidemiology | Female | Zollinger-Ellison Syndrome - pathology | Gastrinoma - pathology | Glucagonoma - pathology | Somatostatinoma - epidemiology | Zollinger-Ellison Syndrome - drug therapy | Risk Assessment | Carcinoma, Neuroendocrine - drug therapy | Pancreatic Neoplasms - pathology | Insulinoma - drug therapy | Carcinoma, Neuroendocrine - genetics | Pancreatic Neoplasms - genetics | Survival Rate | Treatment Outcome | Gastrinoma - drug therapy | Carcinoma, Neuroendocrine - pathology | Insulinoma - pathology | Biopsy, Needle | Gastrinoma - epidemiology | Neoplasm Staging | NEUROENDOCRINE TUMORS | LONG-TERM SURVIVAL | CHROMOGRANIN-A | ZOLLINGER-ELLISON-SYNDROME | HIGH-DOSE TREATMENT | OBSTETRICS & GYNECOLOGY | NEURON-SPECIFIC ENOLASE | CARCINOID-TUMORS | ISLET-CELL TUMORS | SOMATOSTATIN RECEPTOR SCINTIGRAPHY | MEDICAL ONCOLOGY GROUP | Biological response modifiers | Somatostatin | Tumors | Index Medicus | Carcinoma; Neuroendocrine/drug therapy/epidemiology/genetics/pathology | Comparative Study | Glucagonoma/drug therapy/epidemiology/pathology | Pancreatic Neoplasms/drug therapy/epidemiology/genetics/pathology | Gastrinoma/drug therapy/epidemiology/pathology | Zollinger-Ellison Syndrome/drug therapy/epidemiology/pathology | Insulinoma/drug therapy/epidemiology/pathology | Biopsy; Needle | Somatostatinoma/drug therapy/epidemiology/pathology
Journal Article
Best Practice & Research: Clinical Gastroenterology, ISSN 1521-6918, 2013, Volume 26, Issue 6, pp. 737 - 753
Abstract Pancreatic neuroendocrine tumors (pNETs) comprise with gastrointestinal carcinoids, the main groups of gastrointestinal neuroendocrine tumors... 
Gastroenterology and Hepatology | Nonfunctional pancreatic endocrine tumor (NF-pNET) | Zollinger-Ellison syndrome (ZES) | Insulinoma | Von Hippel Lindau disease (VHL) | Tuberous sclerosis | Neuroendocrine tumor (NET) | Gastrinoma | VIPoma | Somatostatinoma | Hypergastrinemia | Neurofibromatosis 1(NF-1) | Growth hormone-releasing factor secreting tumor (GRPoma) | hypoglycemia | Glucagonoma | Pancreatic neuroendocrine tumor (pNET) | Von Recklinghausen's disease | Pancreatic polypeptide secreting tumor (PPoma) | Multiple endocrine neoplasia type 1(MEN1) | INSULINOMA PATIENTS | ENETS CONSENSUS GUIDELINES | ECTOPIC SECRETION | ZOLLINGER-ELLISON-SYNDROME | ENDOCRINE NEOPLASIA TYPE-1 | WELL | SURGICAL-MANAGEMENT | SERUM GASTRIN | INSTITUTES-OF-HEALTH | ISLET-CELL TUMORS | GASTROENTEROLOGY & HEPATOLOGY | Neurofibromatosis 1 (NF-1) | Pancreatic Neoplasms - metabolism | Receptors, Somatostatin - therapeutic use | Pancreatic Neoplasms - diagnosis | Humans | Somatostatinoma - diagnosis | Neuroendocrine Tumors - diagnosis | Zollinger-Ellison Syndrome - therapy | Molecular Targeted Therapy | Receptors, Somatostatin - classification | Zollinger-Ellison Syndrome - diagnosis | Somatostatinoma - therapy | Gastrointestinal Neoplasms - metabolism | Vipoma - diagnosis | Neuroendocrine Tumors - metabolism | Pancreatic Neoplasms - genetics | Gastrointestinal Neoplasms - diagnosis | Gastrointestinal Neoplasms - therapy | Insulinoma - therapy | Glucagonoma - diagnosis | Insulinoma - diagnosis | Neuroendocrine Tumors - genetics | Vipoma - therapy | Neuroendocrine Tumors - therapy | Glucagonoma - therapy | Pancreatic Neoplasms - therapy | Chemotherapy | Diagnosis | Tumors | Cancer | Index Medicus | glucagonoma | somatostatinoma | pancreatic neuroendocrine tumor (pNET) | hypergastrinemia | von Recklinghausen’s disease | tuberous sclerosis | pancreatic polypeptide secreting tumor (PPoma) | nonfunctional pancreatic endocrine tumor (NF-pNET) | Zollinger- Ellison syndrome (ZES) | neuroendocrine tumor (NET) | insulinoma | Multiple Endocrine Neoplasia type 1(MEN1) | von Hippel Lindau disease (VHL) | gastrinoma | neurofibromatosis 1(NF-1)
Journal Article